Michael A. Caligiuri, MD
Director, Comprehensive Cancer Center
CEO, James Cancer Hospital &
  Solove Research Institute
JL Marakas Nationwide Insurance Enterprise
  Foundation Professor of Cancer Research
The Ohio State University
300 W. 10th Ave, Suite 521B
Columbus,OH. 43210
Phone: 614) 293-7521
Fax: (614) 293-7522
michael.caligiuri@osumc.edu

In July 2003, Dr. Caligiuri, a medical scientist who has conducted extensive research in leukemia, lymphoma and immunology, was named director of the OSU Comprehensive Cancer Center (OSUCCC) and deputy director of The James Cancer Hospital and Solove Research Institute. He also chairs the Division of Hematology and Oncology in the OSU College of Medicine and Public Health, Department of Internal Medicine. In addition, he is a professor of medicine and a Distinguished University Scholar who holds the John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research. Caligiuri's laboratory, which has nearly 40 members, focuses on research in leukemia, lymphoma and the human immune system. His current projects include developing a vaccine to prevent lymphoma in organ transplant patients and working to target genetic defects in leukemia and lymphoma for curative therapies. Research efforts led by Caligiuri at OSU have received more than $20 million from the National Cancer Institute, including a $9.5 million program project grant to study immunity in cancer. Caligiuri earned his graduate and medical degrees at Stanford University School of Medicine, then trained in internal medicine, oncology, bone marrow transplantation and immunology at Harvard before joining the Harvard Medical School faculty in 1989. He later went to Roswell Park Medical Center in Buffalo, NY, and was recruited to the OSUCCC in 1997 as associate director for clinical research. He has more than 130 publications in scientific journals.

Education
S.U.N.Y. at Buffalo B.A. 1978 Humanities
Stanford University M.A. 1982 Physiology
Stanford University M.D. 1983 Medicine

Current Publications
EBV kidney allograft infection: possible relationship with a peri-graft localization of PTLD.
Porcu P, Caligiuri MA Am J Trans 4(1): 116-123, 2004.

Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox Perrotti D, Marcucci G, Caligiuri MA J Clin Oncol in press: , 2004

NK cell and DC interactions. Caligiuri MA Trends Immunol 25(1): 47-52, 2004

A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Caligiuri MA, Bloomfield CD Proc Natl Acad Sci USA in press: 2003.

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study Whitman SP, Marcucci G, Caligiuri MA, de la Chapelle A, Bloomfield CD. Blood 102(5): 1613-1618, 2003

BAALC, a novel marker of human hematopoietic progenitor cells. Kusewitt DF, Caligiuri MA, Bloomfield CD, de la Chapelle A. Exp Hematol 31(11): 1051-1056, 2003.

BCR/ABL activates mdm2 mRNA translation via the La antigen. Caligiuri MA. Cancer Cell 3(2): 145-160, 2003.

Biology and clinical impact of human natural killer cells. Farag SS, Caligiuri MA. Int J Hematol 78(1): 7-17, 2003.

Cancer T- cell therapy expands. Caligiuri MA. Nat Med 9(3): 257-258, 2003.

Characterization of leukemia-associated Rho guanine nucleotide exchange factor (LARG) expression during murine development. Caligiuri MA, Marcucci G. Cell Tissue Res 314(3): 361-366, 2003.

Core binding factor (CBF) primary acute myeloid leukemia: Is the molecular monitoring by RT-PCR useful clinically. Marcucci G, Bloomfield CD, Caligiuri MA. Eur J Haematol 71(3): 143-154, 2003.

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Caligiuri MA. Proc Natl Acad Sci USA 100(13): 7830-7835, 2003.

Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Eisenbeis CF, Ferketich A, *Moeschberger M, Porcu P, Barth RF, Caligiuri MA.  Cancer Res 63(5): 965-971, 2003.

New developments in anti-tumor efficacy and malignant transformation of human natural killer cells. Caligiuri MA. Curr Opin Hematol 10(1): 55-59, 2003.

New directions in natural killer cell-based immunotherapy of human cancer. Farag SS, Caligiuri MA. Expert Opin Biol Ther 3(2): 237-250, 2003.

Phase I and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Marcucci G, Byrd JC, *Young DC, Chan KK, Porcu P, Farag SS, Kraut EH, Bloomfield CD, Grever MR, Caligiuri MA. Blood 101(2): 425-432, 2003.

Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma. Eisenbeis CF, Caligiuri MA, Byrd JC. Clin Cancer Res 9(16): 5810-5812, 2003.